Immunome (IMNM) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
Immunome insider trading at a glance (Oct 9, 2026): in the past 12 months, 3 insiders bought $2.3M and 7 sold $27.5M of IMNM stock on the open market.
Get emailed when insiders cluster-buy stocks like IMNM
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
IMNM insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $11.7M | 15 |
| Q2 2026 | $308K | 4 | $6.2M | 9 |
| Q1 2026 | $544K | 3 | $1.3M | 2 |
| Q4 2025 | $1.5M | 4 | $8.3M | 2 |
Valuation, profit and volume
Summary
Over the past 12 months, 3 Immunome Inc. insiders reported open-market purchases totaling $2.3M, while 7 insiders reported sales totaling $27.5M. Among insiders with enough purchase history to measure, Clay B Siegall (CEO, President) has the highest Insider Score at 66. 24 of 28 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 15SEC | Jack HigginsChief Scientific Officer | Sell Plan | 13,20065,050 held (−17%) | $25.32 | $334K | -22.8% | — |
| Aug 12SEC | Isaac BarchasDirector | Sell Plan | 62,291 | $26.23 | $1.6M | -25.5% | — |
| Aug 12SEC | Isaac BarchasDirector | Sell Plan | 11,04892,211 held (−11%) | $27.25 | $301K | -28.3% | — |
| Aug 12SEC | Isaac BarchasDirector | Sell Plan | 10,12562,291 held (−14%) | $26.07 | $264K | -25.0% | — |
| Aug 10SEC | Isaac BarchasDirector | Sell Plan | 20,84087,664 held (−19%) | $26.06 | $543K | -25.0% | — |
| Aug 10SEC | Isaac BarchasDirector | Sell Plan | 15,24872,416 held (−17%) | $26.06 | $397K | -25.0% | — |
| Aug 6SEC | Kinney HornChief Business Officer | Sell Plan | 90,616 | $25.09 | $2.3M | -22.1% | — |
| Jul 9SEC | Kinney HornChief Business Officer | Sell Plan | 1,092 | $25.00 | $27K | -21.8% | — |
| Jul 7SEC | Isaac BarchasDirector | Sell Plan | 83,094125,410 held (−40%) | $24.11 | $2.0M | -18.9% | — |
| Jul 7SEC | Robert LechleiderChief Medical Officer | Sell Plan | 22,71448,091 held (−32%) | $21.95 | $499K | -10.9% | — |
| Jul 7SEC | Isaac BarchasDirector | Sell Plan | 16,906108,504 held (−13%) | $24.20 | $409K | -19.2% | — |
| Jul 7SEC | Robert LechleiderChief Medical Officer | Sell Plan | 16,07215,805 held (−50%) | $23.44 | $377K | -16.6% | — |
| Jul 7SEC | Robert LechleiderChief Medical Officer | Sell Plan | 16,21431,877 held (−34%) | $22.76 | $369K | -14.1% | — |
| Jul 2SEC | Isaac BarchasDirector | Sell Plan | 101,050308,504 held (−25%) | $21.12 | $2.1M | -7.4% | — |
| Jul 2SEC | Isaac BarchasDirector | Sell Plan | 75,665232,839 held (−25%) | $22.35 | $1.7M | -12.5% | — |
| Jul 2SEC | Isaac BarchasDirector | Sell Plan | 24,335208,504 held (−10%) | $23.33 | $568K | -16.2% | — |
| Jun 29SEC | Robert LechleiderChief Medical Officer | Sell Plan | 40,58030,225 held (−57%) | $19.56 | $794K | -0.1% | — |
| Jun 29SEC | Robert LechleiderChief Medical Officer | Sell Plan | 14,42015,805 held (−48%) | $20.66 | $298K | -5.4% | — |
| Jun 17SEC | Max RosettCFO | Sell Plan | 60,00054,037 held (−53%) | $18.23 | $1.1M | +7.2% | — |
| Jun 9SEC | Jean Jacques BienaimeDirector | Sell | 10,00032,915 held (−23%) | $19.41 | $194K | +0.7% | 66 |
| Jun 9SEC | Jean Jacques BienaimeDirector | Buy | 6,00038,915 held (+18%) | $19.48 | $117K | +0.4% | 66 |
| Jun 9SEC | Jean Jacques BienaimeDirector | Buy | 3,50042,415 held (+9%) | $19.46 | $68K | +0.5% | 66 |
| Jun 9SEC | Jean Jacques BienaimeDirector | Buy | 1,00043,415 held (+2%) | $19.27 | $19K | +1.5% | 66 |
| Jun 9SEC | Jean Jacques BienaimeDirector | Sell | 50042,915 held (−1%) | $19.44 | $10K | +0.6% | 66 |
| May 19SEC | Jean Jacques BienaimeDirector | Buy | 5,00043,415 held (+13%) | $20.70 | $104K | -5.6% | 66 |
| Apr 3SEC | Max RosettCFO | Sell Plan | 63,65655,381 held (−53%) | $21.91 | $1.4M | -10.8% | — |
| Apr 3SEC | Jack HigginsChief Scientific Officer | Sell Plan | 9,43822,000 held (−30%) | $21.64 | $204K | -9.7% | — |
| Apr 3SEC | Max RosettCFO | Sell Plan | 1,34454,037 held (−2%) | $22.48 | $30K | -13.0% | — |
| Mar 31SEC | Clay B SiegallCEO, President | Buy | 25,450690,704 held (+4%) | $19.67 | $501K | -0.6% | 66 |
| Mar 23SEC | Philip WagenheimDirector | Sell | 36,800369,347 held (−9%) | $20.47 | $753K | -4.5% | — |
| Mar 23SEC | Philip WagenheimDirector | Sell | 28,200341,147 held (−8%) | $20.65 | $582K | -5.3% | — |
| Mar 12SEC | Jean Jacques BienaimeDirector | Buy | 1,00037,415 held (+3%) | $22.12 | $22K | -11.6% | 66 |
| Mar 12SEC | Jean Jacques BienaimeDirector | Buy | 1,00038,415 held (+3%) | $21.55 | $22K | -9.3% | 66 |
| Dec 30SEC | Clay B SiegallCEO, President | Buy | 4,729665,254 held (+1%) | $21.15 | $100K | -7.6% | 66 |
| Dec 23SEC | Isaac BarchasDirector | Sell Plan | 371,9492,042,432 held (−15%) | $21.72 | $8.1M | -10.0% | — |
| Dec 23SEC | Isaac BarchasDirector | Sell Plan | 11,2512,031,181 held (−1%) | $22.34 | $251K | -12.5% | — |
| Dec 22SEC | Philip TsaiChief Technical Officer | Buy | 10,00043,300 held (+30%) | $20.49 | $205K | -4.6% | — |
| Dec 22SEC | Clay B SiegallCEO, President | Buy | 7,278860,525 held (+1%) | $20.48 | $149K | -4.5% | 66 |
| Dec 18SEC | Clay B SiegallCEO, President | Buy | 46,511853,247 held (+6%) | $21.50 | $1000K | -9.1% | 66 |
Insiders at Immunome Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Isaac BarchasDirector | — | $18.3M | Aug 12, 2026 | — |
| Clay B SiegallCEO, President | $1.7M | — | Mar 31, 2026 | 66 |
| Max RosettCFO | — | $2.5M | Jun 17, 2026 | — |
| Robert LechleiderChief Medical Officer | — | $2.3M | Jul 7, 2026 | — |
| Kinney HornChief Business Officer | — | $2.3M | Aug 6, 2026 | — |
| Philip WagenheimDirector | — | $1.3M | Mar 23, 2026 | — |
| Jean Jacques BienaimeDirector | $351K | $204K | Jun 9, 2026 | 66 |
| Philip TsaiChief Technical Officer | $205K | — | Dec 22, 2025 | — |
| Jack HigginsChief Scientific Officer | — | $538K | Sep 15, 2026 | — |
IMNM stock: common questions
Are Immunome Inc. insiders buying IMNM stock?
In the past 12 months, 3 insiders reported open-market purchases of IMNM worth $2.3M. The latest was Director Jean Jacques Bienaime bought $117K of IMNM at $19.48 — largest purchase by this insider in our records.
Are Immunome Inc. insiders selling IMNM stock?
7 insiders reported sales worth $27.5M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is IMNM's 52-week range?
Over the past year IMNM has traded between $13.92 and $29.82. It last closed at $19.55 on Oct 9, 2026.